These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 7438053)

  • 1. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro.
    Erickson LC; Ramonas LM; Zaharko DS; Kohn KW
    Cancer Res; 1980 Nov; 40(11):4216-20. PubMed ID: 7471062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of monomeric and polymeric cyclophosphamide derivatives compared with in vitro hydrolysis.
    Hirano T; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Jul; 40(7):2263-7. PubMed ID: 7388792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical antitumor activity of bizelesin in mice.
    Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
    Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with cyclophosphamide and ftorafur against advanced L1210 murine leukemia.
    Grossie VB; Rosenblum MG; Loo TL
    Cancer Treat Rep; 1982 Aug; 66(8):1631-4. PubMed ID: 6809329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antitumor properties in rodents of irreversible inhibitors of L-ornithine decarboxylase, used as such or as prodrugs.
    Claverie N; Mamont PS
    Cancer Res; 1989 Aug; 49(16):4466-71. PubMed ID: 2501026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive values of the in vivo diffusion chamber for cyclophosphamide treatment of L1210 murine leukemia.
    Anderson KC; Humphrey RL; Sensenbrenner LL
    Cancer Res; 1983 May; 43(5):2030-3. PubMed ID: 6831434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of treatment schedule on antitumor activity of glycolate-0,0'-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II).
    Suzumura Y; Kato T; Ueda R; Ota K
    Anticancer Res; 1989; 9(4):1083-8. PubMed ID: 2817790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.
    Bradner WT; Rose WC; Schurig JE; Schlein A; Huftalen JB
    Cancer Res; 1984 Dec; 44(12 Pt 1):5619-23. PubMed ID: 6437670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
    Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
    J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
    Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.
    Li LH; DeKoning TF; Kelly RC; Krueger WC; McGovren JP; Padbury GE; Petzold GL; Wallace TL; Ouding RJ; Prairie MD
    Cancer Res; 1992 Sep; 52(18):4904-13. PubMed ID: 1516047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.
    Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M
    Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
    Borden EC; Sidky YA; Hatcher JF; Bryan GT
    Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of antitumor effect of cyclophosphamide by thaliblastine in Lewis lung carcinoma and L1210 leukemia in mice.
    Stoychkov JN; Miloushev AS
    Biomedicine; 1980 Apr; 33(2):42-4. PubMed ID: 6447522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experiment to potentiate the effect of cyclophosphamide combined with tempidon and caffeine in leukemia L1210 and Lewis hepatic carcinoma].
    Stoichkov I; Milushev A; Todorov D
    Eksp Med Morfol; 1978; 17(1):9-14. PubMed ID: 639751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity and preliminary drug disposition studies on chartreusin (NSC 5159).
    McGovren JP; Neil GL; Crampton SL; Robinson MI; Douros JD
    Cancer Res; 1977 Jun; 37(6):1666-72. PubMed ID: 870180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.